Dolores Cejalvo-Lapeña

Prof. Dolores Cejalvo-Lapeña

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2018 in Respiratory Research
Verified
Journal Article
Open access
PDF file
JMJavier Milara
Javier Milara
GHGracia Hernandez
Gracia Hernandez
BLBeatriz Ballester Llobell
Beatriz Ballester Llobell
AMAnselm Morell
Anselm Morell
ILInés Roger Laparra
Inés Roger Laparra
JCJulio Cortijo
Julio Cortijo
Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal fibrotic disorder, with no curative therapies. The signal transducer and activator of transcription 3 (STAT3) protein is activated in lung fibroblasts and alveolar type II cells (ATII), thereby contributing to lung fibrosis in IPF. Although activation of Janus kinase 2 (JAK2) has been implicated in proliferative disorders, its role in IPF is unknown. The aim of this study was to analyze JAK2 activation in IPF, and to determine whether JAK2/STAT3 inhibition is a potential therapeutic strategy for this disease. JAK2/p-JAK2 and STAT3/pSTAT3 expression was evaluated using quantitative real time-PCR, western blotting, and immunohistochemistry. Compared to human healthy lung tissue (n = 10) both proteins were upregulated in the lung tissue of IPF patients (n = 12). Stimulating primary ATII and lung fibroblasts with transforming growth factor beta 1 or interleukin (IL)-6/IL-13 activated JAK2 and STAT3, inducing epithelial to mesenchymal and fibroblast to myofibroblast transitions. Dual p-JAK2/p-STAT3 inhibition with JSI-124 or silencing of JAK2 and STAT3 genes suppressed ATII and the fibroblast to myofibroblast transition, with greater effects than the sum of those obtained using JAK2 or STAT3 inhibitors individually. Dual rather than single inhibition was also more effective for inhibiting fibroblast migration, preventing increases in fibroblast senescence and Bcl-2 expression, and ameliorating impaired autophagy. In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day, bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2 and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis. JAK2 and STAT3 are activated in IPF, and their dual inhibition may be an attractive strategy for treating this disease.

17 June 2013 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña
DLDolores Cejalvo Lapeña
Dolores Cejalvo Lapeña
ATAlexander Horacio Toledo
Alexander Horacio Toledo
CFCristobal Zaragoza Fernandez
Cristobal Zaragoza Fernandez
LPLuis Horacio Toledo Pereyra
Luis Horacio Toledo Pereyra
Pentoxifylline, a methylxanthine derivative with significant hemorheologic properties, is used for claudication in patients with peripheral vascular disease, and experimentally for ischemic injury to organs because of its antioxidant and antiinflammatory effects. We used a rat model of severe small intestinal ischemia and reperfusion to determine the ability of pentoxifylline in improving survival, molecular response, and pathological protection. We used 6 groups of male Wistar rats (n=25 each). The superior mesenteric artery was occluded for 120 minutes. Laboratory and tissue studies were done on 5 animals, 1 hour after reperfusion, and animal survival was assessed at 7 days. There were 2 control groups that received normal saline, either before ischemia or during reperfusion. The 4 treated groups received pentoxifylline 1 or 10 mg/kg at the same times mentioned above. Laboratory studies included measuring serum lactic acid dehydrogenase, tumor necrosis factor-α, interleukin-1β, and interleukin-6.Intestinal tissue malondialdehyde and myeloperoxidase in small intestine tissue also were measured. Histology and laser vascular blood flow at baseline and reperfusion were obtained, and survival was determined 7 days after ischemia. A significant survival benefit in the animals treated with 10 mg/kg of pentoxifylline at reperfusion was noted. This coincided with a reduction in biochemical markers of cell damage - specifically, serum lactic acid dehydrogenase, and tissue malondialdehyde, ischemia, and reperfusion. Additionally, we saw decreased levels of tumor necrosis factor-α, interleukin-1β, and interleukin-6. Improved postreperfusion blood flow shown by laser Doppler technology also was seen in the treated groups. Histologically, we observed less neutrophil infiltration in the intestine of ischemic-treated rats. Also seen in the control animals were increased necrotic lesions in the microvilli with a higher presence of lysozyme in the Paneth cells. Survival was significantly better at 7 days (70% vs 40%) when we compared the pentoxifylline group treated at reperfusion (10 mg/kg) to the ischemic controls. Pentoxifylline had a significant protective effect on severely ischemic bowel when administered during reperfusion at a dosage of 10 mg/kg. Better survival, improved histology, and molecular response should urge consideration of the consideration of applying these findings in some general surgery and transplant conditions.

27 December 2023 in Journal of Applied Phycology
Verified
Journal Article
Closed access
PDF file
SGSamanta García-Oms
Samanta García-Oms
SBSánchez- Bonet
Sánchez- Bonet
DEDesirée
Desirée
Mariola Belda-AntolíMariola Belda-Antolí
Mariola Belda-Antolí
CPCarolina Padrón-Sanz
Carolina Padrón-Sanz
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña

11 May 2016 in Wound Repair and Regeneration
Verified
Journal Article
Closed access
PDF file
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña
JBJaime Ballester‐Álvaro
Jaime Ballester‐Álvaro
CBCarlos Barrios
Carlos Barrios
CZCristobal Zaragozá‐Fernández
Cristobal Zaragozá‐Fernández
CCCarlos Gómez‐De la Cruz
Carlos Gómez‐De la Cruz
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña

11 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBCarlos Barrios
Carlos Barrios
BPBeatriz Prieto-Moure
Beatriz Prieto-Moure
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña
Renal injuries are relatively common in cases of abdominal trauma. Adhesives and sealants can be used to repair and preserve damaged organs. Using a rat model, this study explores the activity of different matrix metalloproteinases (MMP) during the healing of renal injuries treated by two biological adhesives (TachoSil and GelitaSpon) and a new synthetic elastic cyanoacrylate (Adhflex). Renal traumatic injuries were experimentally induced in 90 male Wistar rats by a Stiefel Biopsy Punch in the anterior aspect of the left kidney. Animals were divided into five groups: 1, sham non-injured (n = 3); 2, non-treated standard punch injury (n = 6); 3, punch injury treated with TachoSil (n = 27); 4, punch injury treated with GelitaSpon (n = 27); and, 5, punch injury treated with Adhflex (n = 27). Wound healing was evaluated 2, 6, and 18 days after injury by determining the expression of MMPs, and the histopathological evolution of lesions. Histologically, the wound size at 6 days post-injury was larger in Adhflex-treated samples than in the other treatments, but the scarring tissue was similar at 18 days post-injury. Only the MMPs subtypes 1, 2, 8, 9, and 13 were sufficiently expressed to be quantifiable. Both time since injury and treatment type had a significant influence on MMPs expression. Two days after injury, the expression of MMP8 and MMP9 was predominant. MMP2 expression was greater 6 days after injury. The Adhflex-treated group had a significantly higher MMPs expression than the other treatment groups at all healing stages. All three sealant treatments induced almost similar expression of MMPs than untreated animals indicating a physiological healing process. Given that all renal trauma injuries must be considered emergencies, both biological and synthetic adhesives, such as Adhflex, should be considered as a treatment options.

23 May 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
DBDesirée Sánchez Bonet
Desirée Sánchez Bonet
CPCarolina Padrón-Sanz
Carolina Padrón-Sanz
JLJosé Miguel Lloris-Cejalvo
José Miguel Lloris-Cejalvo
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña
DCDolores Cejalvo-Lapeña
Dolores Cejalvo-Lapeña
Fucus vesiculosus is a brown seaweed known for its strong antioxidant properties, mainly attributed to its high polyphenolic content. This study aimed to evaluate the antioxidant protective effect of an optimised F. vesiculosus extract in an experimental model of intestinal ischemia/reperfusion (I/R) injury, considering the intestine as particularly vulnerable to this pathology. Seventy-two male Wistar albino rats were randomly divided into twelve groups: Sham, I/R groups (3 and 24 h reperfusion), I/R plus vehicle groups (three application times, 3 h reperfusion), and I/R plus F. vesiculosus extract groups (three application times, 3 and 24 h reperfusion). Intestinal injury was assessed through biochemical markers (malondialdehyde [MDA], superoxide dismutase [SOD], catalase [CAT], glutathione peroxidase [GPx], and mieloperoxidase [MPO]), inflammatory cytokines (interleukin 1 β [IL-1β] and interleukin [IL-10]), and histological analysis. Results demonstrated that treatment with F. vesiculosus significantly reduced oxidative stress and inflammation caused by I/R injury (p < 0.05), restoring analysed parameters (MDA, SOD, CAT, IL-10) to levels comparable to the Sham group. Histological examination confirmed the preservation of intestinal mucosal integrity following F. vesiculosus administration. These findings suggest that the antioxidant extract from F. vesiculosus effectively protects against intestinal I/R injury, highlighting its potential for clinical use in preventing and managing this pathological condition, particularly in surgical contexts.